{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:44:10Z","timestamp":1791582250570,"version":"4.3.4"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Accelerated progression of chronic obstructive pulmonary disease (COPD) is associated with increased risks of hospitalization and death. Prognostic insights into mechanisms and markers of progression could facilitate development of disease-modifying therapies. Although individual biomarkers exhibit some predictive value, performance is modest and their univariate nature limits network-level insights. To overcome these limitations and gain insights into early pathways associated with rapid progression, we measured 1305 peripheral blood and 48 bronchoalveolar lavage proteins in individuals with COPD [n\u2009=\u200945, mean initial forced expiratory volume in one second (FEV<jats:sub>1<\/jats:sub>) 75.6\u2009\u00b1\u200917.4% predicted]. We applied a data-driven analysis pipeline, which enabled identification of protein signatures that predicted individuals at-risk for accelerated lung function decline (FEV<jats:sub>1<\/jats:sub> decline\u2009\u2265\u200970\u00a0mL\/year)\u2009~\u20096\u00a0years later, with high accuracy. Progression signatures suggested that early dysregulation in elements of the complement cascade is associated with accelerated decline. Our results propose potential biomarkers and early aberrant signaling mechanisms driving rapid progression in COPD.<\/jats:p>","DOI":"10.1038\/s41598-023-32216-0","type":"journal-article","created":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T09:02:41Z","timestamp":1684746161000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["A blood and bronchoalveolar lavage protein signature of rapid FEV1 decline in smoking-associated COPD"],"prefix":"10.1038","volume":"13","author":[{"given":"Katarina M.","family":"DiLillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy C.","family":"Norman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie A.","family":"Christenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil E.","family":"Alexis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne H.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor Z.","family":"Barjaktarevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Graham","family":"Barr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro P.","family":"Comellas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene R.","family":"Bleecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard C.","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Couper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard J.","family":"Criner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire M.","family":"Doerschuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Michael","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MeiLan K.","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric A.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia N.","family":"Hansel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette T.","family":"Hastie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Kaner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry A.","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wassim W.","family":"Labaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando J.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah A.","family":"Meyers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanda K.","family":"O\u2019Neal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor E.","family":"Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Robert","family":"Paine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen P.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prescott G.","family":"Woodruff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell P.","family":"Bowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly B.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"SPIROMICS investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,22]]},"reference":[{"key":"32216_CR1","unstructured":"Kochanek, K. D., Xu, J. & Arias, E. Mortality in the United States, 2019. NCHS Data Brief, no 395 (2020)."},{"key":"32216_CR2","unstructured":"Akinbami, L. J. & Liu, X. Chronic obstructive pulmonary disease among adults aged 18 and over in the United States, 1998\u20132009. NCHS Data Brief, no 63 (2011)."},{"key":"32216_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1378\/chest.14-0972","volume":"147","author":"ES Ford","year":"2015","unstructured":"Ford, E. S. et al. Total and state-specific medical and absenteeism costs of COPD among adults aged \u2265 18 years in the United States for 2010 and projections through 2020. Chest 147, 31\u201345 (2015).","journal-title":"Chest"},{"key":"32216_CR4","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1164\/rccm.201105-0831OC","volume":"184","author":"C Casanova","year":"2011","unstructured":"Casanova, C. et al. The progression of chronic obstructive pulmonary disease is heterogeneous: The experience of the BODE cohort. Am. J. Respir. Crit. Care Med. 184, 1015\u20131021 (2011).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"32216_CR5","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1164\/rccm.201106-0992OC","volume":"185","author":"M Nishimura","year":"2012","unstructured":"Nishimura, M. et al. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 185, 44\u201352 (2012).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"32216_CR6","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1164\/rccm.200508-1344OC","volume":"173","author":"DM Mannino","year":"2006","unstructured":"Mannino, D. M., Reichert, M. M. & Davis, K. J. Lung function decline and outcomes in an adult population. Am. J. Respir. Crit. Care Med. 173, 985\u2013990 (2006).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"32216_CR7","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1056\/NEJMoa1105482","volume":"365","author":"J Vestbo","year":"2011","unstructured":"Vestbo, J. et al. Changes in forced expiratory volume in 1 second over time in COPD. N. Engl. J. Med. 365, 1184\u20131192 (2011).","journal-title":"N. Engl. J. Med."},{"key":"32216_CR8","doi-asserted-by":"crossref","unstructured":"Zemans, R. L. et al. Multiple biomarkers predict disease severity, progression and mortality in COPD. Respir. Res. 18, (2017).","DOI":"10.1186\/s12931-017-0597-7"},{"key":"32216_CR9","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1164\/rccm.201305-0892OC","volume":"188","author":"HY Park","year":"2013","unstructured":"Park, H. Y. et al. Club cell protein 16 and disease progression in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 188, 1413\u20131419 (2013).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"32216_CR10","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.rmed.2009.01.021","volume":"103","author":"Y Higashimoto","year":"2009","unstructured":"Higashimoto, Y. et al. Serum biomarkers as predictors of lung function decline in chronic obstructive pulmonary disease. Respir. Med. 103, 1231\u20131238 (2009).","journal-title":"Respir. Med."},{"key":"32216_CR11","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12931-017-0662-2","volume":"18","author":"E Bradford","year":"2017","unstructured":"Bradford, E. et al. The value of blood cytokines and chemokines in assessing COPD. Respir. Res. 18, 180 (2017).","journal-title":"Respir. Res."},{"key":"32216_CR12","doi-asserted-by":"publisher","first-page":"e000431","DOI":"10.1136\/bmjresp-2019-000431","volume":"6","author":"BR Celli","year":"2019","unstructured":"Celli, B. R. et al. Serum biomarkers and outcomes in patients with moderate COPD: A substudy of the randomised SUMMIT trial. BMJ Open Respir. Res. 6, e000431 (2019).","journal-title":"BMJ Open Respir. Res."},{"key":"32216_CR13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1093\/aje\/kwt208","volume":"179","author":"S Ahmadi-Abhari","year":"2014","unstructured":"Ahmadi-Abhari, S., Kaptoge, S., Luben, R. N., Wareham, N. J. & Khaw, K. T. Longitudinal association of C-reactive protein and lung function over 13 years: The EPIC-Norfolk study. Am. J. Epidemiol. 179, 48\u201356 (2014).","journal-title":"Am. J. Epidemiol."},{"key":"32216_CR14","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1136\/thx.2006.066969","volume":"62","author":"AW Fogarty","year":"2007","unstructured":"Fogarty, A. W., Jones, S., Britton, J. R., Lewis, S. A. & McKeever, T. M. Systemic inflammation and decline in lung function in a general population: A prospective study. Thorax 62, 515\u2013520 (2007).","journal-title":"Thorax"},{"key":"32216_CR15","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1513\/AnnalsATS.201408-351OC","volume":"11","author":"M Suzuki","year":"2014","unstructured":"Suzuki, M. et al. Lower leptin\/adiponectin ratio and risk of rapid lung function decline in chronic obstructive pulmonary disease. Ann. Am. Thorac. Soc. 11, 1511\u20131519 (2014).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"32216_CR16","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1039\/C5MB00577A","volume":"12","author":"Z Liu","year":"2016","unstructured":"Liu, Z. et al. Identification of potential COPD genes based on multi-omics data at the functional level. Mol. Biosyst. 12, 191\u2013204 (2016).","journal-title":"Mol. Biosyst."},{"key":"32216_CR17","first-page":"5247","volume":"17","author":"P Zhao","year":"2018","unstructured":"Zhao, P. et al. Integration of transcriptomics, proteomics, metabolomics and systems pharmacology data to reveal the therapeutic mechanism underlying Chinese herbal Bufei Yishen formula for the treatment of chronic obstructive pulmonary disease. Mol. Med. Rep. 17, 5247\u20135257 (2018).","journal-title":"Mol. Med. Rep."},{"key":"32216_CR18","doi-asserted-by":"publisher","first-page":"1701930","DOI":"10.1183\/13993003.01930-2017","volume":"51","author":"CX Li","year":"2018","unstructured":"Li, C. X., Wheelock, C. E., Sk\u00f6ld, C. M. & Wheelock, \u00c5. M. Integration of multi-omics datasets enables molecular classification of COPD. Eur. Respir. J. 51, 1701930 (2018).","journal-title":"Eur. Respir. J."},{"key":"32216_CR19","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1164\/rccm.201810-1860SO","volume":"199","author":"RA Stockley","year":"2019","unstructured":"Stockley, R. A., Halpin, D. M. G., Celli, B. R. & Singh, D. Chronic obstructive pulmonary disease biomarkers and their interpretation. Am. J. Respir. Crit. Care Med. 199, 1195\u20131204 (2019).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"32216_CR20","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1097\/MCP.0000000000000549","volume":"25","author":"DM Mannino","year":"2019","unstructured":"Mannino, D. M. Biomarkers for chronic obstructive pulmonary disease diagnosis and progression: Insights, disappointments and promise. Curr. Opin. Pulm. Med. 25, 144\u2013149 (2019).","journal-title":"Curr. Opin. Pulm. Med."},{"key":"32216_CR21","doi-asserted-by":"publisher","first-page":"12049","DOI":"10.1038\/s41598-020-67956-w","volume":"10","author":"KC Norman","year":"2020","unstructured":"Norman, K. C. et al. Identification of a unique temporal signature in blood and BAL associated with IPF progression. Sci. Rep. 10, 12049 (2020).","journal-title":"Sci. Rep."},{"key":"32216_CR22","doi-asserted-by":"publisher","first-page":"46560","DOI":"10.1038\/srep46560","volume":"7","author":"DN O\u2019Dwyer","year":"2017","unstructured":"O\u2019Dwyer, D. N. et al. The peripheral blood proteome signature of idiopathic pulmonary fibrosis is distinct from normal and is associated with novel immunological processes. Sci. Rep. 7, 46560 (2017).","journal-title":"Sci. Rep."},{"key":"32216_CR23","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s12195-019-00567-2","volume":"12","author":"KC Norman","year":"2019","unstructured":"Norman, K. C. et al. Inference of cellular immune environments in sputum and peripheral blood associated with acute exacerbations of COPD. Cell. Mol. Bioeng. 12, 165\u2013177 (2019).","journal-title":"Cell. Mol. Bioeng."},{"key":"32216_CR24","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1513\/AnnalsATS.201807-441OC","volume":"16","author":"JM Wells","year":"2019","unstructured":"Wells, J. M. et al. Safety and tolerability of comprehensive research bronchoscopy in chronic obstructive pulmonary disease. Results from the SPIROMICS bronchoscopy substudy. Ann. Am. Thorac. Soc. 16, 439\u2013446 (2019).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"32216_CR25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12967-014-0374-z","volume":"13","author":"CM Freeman","year":"2015","unstructured":"Freeman, C. M. et al. Design of a multi-center immunophenotyping analysis of peripheral blood, sputum and bronchoalveolar lavage fluid in the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS). J. Transl. Med. 13, 19 (2015).","journal-title":"J. Transl. Med."},{"key":"32216_CR26","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1136\/thoraxjnl-2013-203897","volume":"69","author":"D Couper","year":"2014","unstructured":"Couper, D. et al. Design of the subpopulations and intermediate outcomes in COPD study (SPIROMICS). Thorax 69, 491\u2013494 (2014).","journal-title":"Thorax"},{"key":"32216_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0177032","volume":"12","author":"R Perez-Padilla","year":"2017","unstructured":"Perez-Padilla, R. et al. Lung function decline in subjects with and without COPD in a population-based cohort in Latin-America. PLoS ONE 12, e0177032 (2017).","journal-title":"PLoS ONE"},{"key":"32216_CR28","doi-asserted-by":"crossref","unstructured":"Anderson, W. et al. Classification of lung function trajectories in SPIROMICS [abstract]. Eur. Respir. J. 58, Suppl 65, PA1858 (2021).","DOI":"10.1183\/13993003.congress-2021.PA1858"},{"key":"32216_CR29","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1165\/rcmb.2018-0245PS","volume":"61","author":"EA Regan","year":"2019","unstructured":"Regan, E. A. et al. Omics and the search for blood biomarkers in chronic obstructive pulmonary disease. Am. J. Respir. Cell Mol. Biol. 61, 143\u2013149 (2019).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"32216_CR30","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jaci.2016.05.011","volume":"138","author":"PJ Barnes","year":"2016","unstructured":"Barnes, P. J. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 138, 16\u201327 (2016).","journal-title":"J. Allergy Clin. Immunol."},{"key":"32216_CR31","doi-asserted-by":"publisher","first-page":"5s","DOI":"10.1183\/09031936.03.00004603a","volume":"22","author":"EJD Oudijk","year":"2003","unstructured":"Oudijk, E. J. D., Lammers, J. W. J. & Koenderman, L. Systemic inflammation in chronic obstructive pulmonary disease. Eur. Respir. Journal, Suppl. 22, 5s-13s (2003).","journal-title":"Eur. Respir. Journal, Suppl."},{"key":"32216_CR32","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1164\/rccm.201710-2028PP","volume":"197","author":"FJ Martinez","year":"2018","unstructured":"Martinez, F. J. et al. At the root: Defining and halting progression of early chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 197, 1540\u20131551 (2018).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"32216_CR33","first-page":"266","volume":"95","author":"RD Miller","year":"1980","unstructured":"Miller, R. D., Kueppers, F. & Offord, K. P. Serum concentrations of C3 and C4 of the complement system in patients with chronic obstructive pulmonary disease. J. Lab. Clin. Med. 95, 266\u2013271 (1980).","journal-title":"J. Lab. Clin. Med."},{"key":"32216_CR34","first-page":"241","volume":"92","author":"S Chauhan","year":"1990","unstructured":"Chauhan, S., Gupta, M. K., Goyal, A. & Dasgupta, D. J. Alterations in immunogolublin & complement levels in chronic obstructive pulmonary disease. Indian J. Med. Res. 92, 241\u2013245 (1990).","journal-title":"Indian J. Med. Res."},{"key":"32216_CR35","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1378\/chest.112.2.341","volume":"112","author":"EN Kosmas","year":"1997","unstructured":"Kosmas, E. N., Zorpidou, D., Vassilareas, V., Roussou, T. & Michaelides, S. Decreased C4 complement component serum levels correlate with the degree of emphysema in patients with chronic bronchitis. Chest 112, 341\u2013347 (1997).","journal-title":"Chest"},{"key":"32216_CR36","doi-asserted-by":"publisher","first-page":"e1700088","DOI":"10.1002\/prca.201700088","volume":"12","author":"A Baralla","year":"2018","unstructured":"Baralla, A. et al. Plasma proteomic signatures in early chronic obstructive pulmonary disease. Proteomics. Clin. Appl. 12, e1700088 (2018).","journal-title":"Proteomics. Clin. Appl."},{"key":"32216_CR37","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/j.1365-3083.2010.02385.x","volume":"71","author":"MM Marc","year":"2010","unstructured":"Marc, M. M. et al. Complement factor C5a in acute exacerbation of chronic obstructive pulmonary disease. Scand. J. Immunol. 71, 386\u2013391 (2010).","journal-title":"Scand. J. Immunol."},{"key":"32216_CR38","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1080\/15412555.2019.1711035","volume":"17","author":"DBA Tan","year":"2020","unstructured":"Tan, D. B. A. et al. Protein network analysis identifies changes in the level of proteins involved in platelet degranulation, proteolysis and cholesterol metabolism pathways in AECOPD patients. COPD J. Chronic Obstr. Pulm. Dis. 17, 29\u201333 (2020).","journal-title":"COPD J. Chronic Obstr. Pulm. Dis."},{"key":"32216_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1006011","volume":"12","author":"W Sun","year":"2016","unstructured":"Sun, W. et al. Common genetic polymorphisms influence blood biomarker measurements in COPD. PLoS Genet. 12, e1006011 (2016).","journal-title":"PLoS Genet."},{"key":"32216_CR40","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3390\/metabo10040124","volume":"10","author":"E Mastej","year":"2020","unstructured":"Mastej, E. et al. Identifying protein\u2013metabolite networks associated with COPD phenotypes. Metabolites 10, 124 (2020).","journal-title":"Metabolites"},{"key":"32216_CR41","first-page":"280","volume":"3","author":"M Mahesh","year":"2016","unstructured":"Mahesh, M., Yalamudi, M. & Lokesh, S. Complement levels in chronic obstructive pulmonary disease: Correlation with pulmonary function and radiological emphysema score. Int. J. Sci. Study 3, 280\u2013284 (2016).","journal-title":"Int. J. Sci. Study"},{"key":"32216_CR42","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/mi.2014.118","volume":"8","author":"X Yuan","year":"2015","unstructured":"Yuan, X. et al. Activation of C3a receptor is required in cigarette smoke-mediated emphysema. Mucosal Immunol. 8, 874\u2013885 (2015).","journal-title":"Mucosal Immunol."},{"key":"32216_CR43","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1165\/rcmb.2003-0394OC","volume":"31","author":"MM Marc","year":"2004","unstructured":"Marc, M. M. et al. Complement factors C3a, C4a, and C5a in chronic obstructive pulmonary disease and asthma. Am. J. Respir. Cell Mol. Biol. 31, 216\u2013219 (2004).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"32216_CR44","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1165\/rcmb.2017-0405OC","volume":"60","author":"HS Kulkarni","year":"2019","unstructured":"Kulkarni, H. S. et al. Intracellular C3 protects human airway epithelial cells from stress-associated cell death. Am. J. Respir. Cell Mol. Biol. 60, 144\u2013157 (2019).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"32216_CR45","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1111\/j.1440-1843.2010.01808.x","volume":"15","author":"SS Sohal","year":"2010","unstructured":"Sohal, S. S. et al. Reticular basement membrane fragmentation and potential epithelial mesenchymal transition is exaggerated in the airways of smokers with chronic obstructive pulmonary disease. Respirology 15, 930\u2013938 (2010).","journal-title":"Respirology"},{"key":"32216_CR46","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.2147\/COPD.S81032","volume":"10","author":"MQ Mahmood","year":"2015","unstructured":"Mahmood, M. Q. et al. Epithelial mesenchymal transition in smokers: large versus small airways and relation to airflow obstruction. Int. J. Chron. Obstruct. Pulmon. Dis. 10, 1515\u20131524 (2015).","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"32216_CR47","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1136\/thoraxjnl-2012-201761","volume":"68","author":"J Milara","year":"2013","unstructured":"Milara, J., Peir\u00f3, T., Serrano, A. & Cortijo, J. Epithelial to mesenchymal transition is increased in patients with COPD and induced by cigarette smoke. Thorax 68, 410\u2013420 (2013).","journal-title":"Thorax"},{"key":"32216_CR48","doi-asserted-by":"crossref","unstructured":"Nishioka, M. et al. Fibroblast-epithelial cell interactions drive epithelial-mesenchymal transition differently in cells from normal and COPD patients. Respir. Res. 16, (2015).","DOI":"10.1186\/s12931-015-0232-4"},{"key":"32216_CR49","doi-asserted-by":"publisher","first-page":"e38629","DOI":"10.1371\/journal.pone.0038629","volume":"7","author":"DA Cockayne","year":"2012","unstructured":"Cockayne, D. A. et al. Systemic biomarkers of neutrophilic inflammation, tissue injury and repair in COPD patients with differing levels of disease severity. PLoS One 7, e38629 (2012).","journal-title":"PLoS One"},{"key":"32216_CR50","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1038\/s41374-018-0049-0","volume":"98","author":"T Lai","year":"2018","unstructured":"Lai, T. et al. Heparin-binding epidermal growth factor contributes to COPD disease severity by modulating airway fibrosis and pulmonary epithelial-mesenchymal transition. Lab. Invest. 98, 1159\u20131169 (2018).","journal-title":"Lab. Invest."},{"key":"32216_CR51","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2217\/bmm-2019-0159","volume":"14","author":"Y Wei","year":"2020","unstructured":"Wei, Y. et al. Prognostic value of cripto-1 expression in non-small-cell lung cancer patients: a systematic review and meta-analysis. Biomark. Med. 14, 317\u2013329 (2020).","journal-title":"Biomark. Med."},{"key":"32216_CR52","doi-asserted-by":"publisher","first-page":"242","DOI":"10.7150\/jca.8486","volume":"5","author":"K Nunomiya","year":"2014","unstructured":"Nunomiya, K. et al. Relationship between serum level of lymphatic vessel endothelial hyaluronan receptor-1 and prognosis in patients with lung cancer. J. Cancer 5, 242\u2013247 (2014).","journal-title":"J. Cancer"},{"key":"32216_CR53","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1164\/rccm.201106-0992OC","volume":"185","author":"M Nishimura","year":"2012","unstructured":"Nishimura, M. et al. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 185, 44\u201352 (2012).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"32216_CR54","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12931-019-1017-y","volume":"20","author":"A Higham","year":"2019","unstructured":"Higham, A., Quinn, A. M., Can\u00e7ado, J. E. D. & Singh, D. The pathology of small airways disease in COPD: historical aspects and future directions. Respir. Res. 20, 49 (2019).","journal-title":"Respir. Res."},{"key":"32216_CR55","doi-asserted-by":"publisher","first-page":"e1900278","DOI":"10.1002\/pmic.201900278","volume":"20","author":"LM Raffield","year":"2020","unstructured":"Raffield, L. M. et al. Comparison of proteomic assessment methods in multiple cohort studies. Proteomics 20, e1900278 (2020).","journal-title":"Proteomics"},{"key":"32216_CR56","doi-asserted-by":"crossref","unstructured":"O\u2019Neal, W. K. et al. Comparison of serum, EDTA plasma and P100 plasma for luminex-based biomarker multiplex assays in patients with chronic obstructive pulmonary disease in the SPIROMICS study. J. Transl. Med. 12, (2014).","DOI":"10.1186\/1479-5876-12-9"},{"key":"32216_CR57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0015004","volume":"5","author":"L Gold","year":"2010","unstructured":"Gold, L. et al. Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS ONE 5, e15004 (2010).","journal-title":"PLoS ONE"},{"key":"32216_CR58","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1148\/radiology.148.3.6878708","volume":"148","author":"JA Hanley","year":"1983","unstructured":"Hanley, J. A. & McNeil, B. J. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148, 839\u2013843 (1983).","journal-title":"Radiology"},{"key":"32216_CR59","doi-asserted-by":"crossref","unstructured":"Zhou, Y. et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat. Commun. 10, (2019).","DOI":"10.1038\/s41467-019-09234-6"},{"key":"32216_CR60","unstructured":"Qian, J., Hastie, T., Friedman, J., Tibshirani, R. & Simon, N. Glmnet for MATLAB. http:\/\/www.stanford.edu\/~hastie\/glmnet_matlab\/ (2013)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32216-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32216-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32216-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T10:22:32Z","timestamp":1684750952000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32216-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,22]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["32216"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-32216-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,22]]},"assertion":[{"value":"31 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KMD, KCN, CMF, SAC, NEA, NEA, WHA, IZB, RGB, APC, EB, RCB, CBC, DJC, GJC, CMD, JMW, EAH, NNH, ATH, RJK, JAK, DAM, WKO, VEO, RP, SPP, PGW, RPB, JLC, KBA have no competing interests to declare. WWL reports personal fees from Konica Minolta and Continuing Education Alliance. MKH reports personal fees from GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Cipla, Chiesi, Novartis, Pulmonx, Teva, Verona, Merck, Mylan, Sanofi, DevPro, Aerogen, Polarian, Regeneron, United Therapeutics, UpToDate, Medscape and Integrity. She has received either in kind research support or funds paid to the institution from the NIH, Novartis, Sunovion, Nuvaira, Sanofi, Astrazeneca, Boehringer Ingelheim, Gala Therapeutics, Biodesix, the COPD Foundation and the American Lung Association. She has participated in Data Safety Monitoring Boards for Novartis and Medtronic with funds paid to the institution. She has received stock options from Meissa Vaccines. FJM. has received personal fees from Forest, Janssen, GlaxoSmithKline, Nycomed\/Takeda, Amgen, AstraZeneca, Boehringer Ingelheim, Ikaria\/ Bellerophon, Genentech, Novartis, Pearl, Pfizer, Roche, Sunovion, Theravance, Axon, CME Incite, California Society for Allergy and Immunology, Annenberg, Integritas, InThough, Miller Medical, National Association for Continuing Education, Paradigm, Peer Voice, UpToDate, Haymarket Communications, Western Society of Allergy and Immunology, Informa, Bioscale, Unity Biotechnology, ConCert, Lucid, Methodist Hospital, Prime, WebMD, Bayer, Ikaria, Kadmon, Vercyte, American Thoracic Society, Academic CME, Falco, Axon Communication, Johnson & Johnson, Clarion, Continuing Education, Potomac, Afferent, and Adept; and has collected nonfinancial support from Boehringer Ingelheim, Centocor, Gilead, and Biogen\/Stromedix; and declares other interests with Mereo, Boehringering Ingelheim, and Centocor. All are outside of this project.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8228"}}